Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient-Focused Listening Sessions For Medicare-Negotiated Drugs: Key Takeaways From Round One

Executive Summary

Pink Sheet infographic breaks down the mix of patient advocacy groups, individual patients and clinicians offering input to CMS on the first 10 drugs facing Medicare price negotiation.

You may also be interested in...



FDA Drug Development Meetings May Be Better Model For Future CMS Patient-Listening Sessions

The ability for Medicare officials to follow-up on patient testimony could make the sessions more informative. They also don’t all have to be the same.

Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate First Medicare Listening Session

Patients and advocacy groups tell Medicare they want lower cost drugs but are concerned that if government negotiations lower list prices, rebate-focused PBMs may preference higher list-price competitors. 

As Medicare Drug Negotiation Patient Sessions Kick Off, Advocates Already Eyeing Improvements

Patient advocates see IRA patient listening sessions as an opening to push CMS to have more conversations on access issues in general, but first they want to work on improving the current process.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel